Can an NP own a weight loss clinic?

Weight-loss clinic ownership for NPs follows the same legal structure as aesthetic medspa ownership. The clinical service mix differs but the ownership chain is the same.

State-by-state structure:

Full Practice Authority states (27 + DC). NP owns the entity (PLLC or PC), holds prescriptive authority, prescribes and manages weight-loss medications independently.

Reduced Practice states (12). NP owns the MSO; a collaborating physician owns the PC under a Management Services Agreement. The collaborating physician serves as medical director and is on the prescriptive authority chain.

Restricted Practice states (10). Same MSO/PC structure. Physician supervision required. The medical director is typically a state-licensed MD or DO.

Service mix considerations specific to weight-loss clinics:

GLP-1 medications (semaglutide, tirzepatide, liraglutide). The dominant weight-loss prescribing category in 2026. Branded products (Wegovy, Mounjaro/Zepbound, Saxenda) through standard pharmacies. Compounded versions through 503A and 503B compounding pharmacies. NPs prescribe under their license (or, in non-Full-Practice states, under the collaborating physician's oversight).

Phentermine / phentermine-topiramate (Qsymia). Schedule IV controlled substance. Requires DEA registration. State-specific telehealth restrictions apply.

Naltrexone / bupropion (Contrave). Non-controlled. NP prescribing common.

Lipotropic / B12 injections. Compounded injectables for energy and metabolism support. NP prescribing common. State-specific compounding pharmacy rules apply.

Hormone therapy (T, peptides, growth-hormone secretagogues). Some weight-loss clinics integrate hormone optimization. Schedule III testosterone requires DEA registration and additional compliance infrastructure.

Operational structure:

Cash-pay model dominant. Most commercial insurance doesn't cover GLP-1 for non-diabetic obesity. Even when covered, deductibles often exceed cash-pay pricing.

Patient onboarding: medical history, lab work (CMP, lipid panel, A1c, TSH; sometimes lipase/amylase), BMI assessment, treatment plan, informed consent.

Monthly or weekly check-ins for first 12 weeks; monthly maintenance.

Side-effect management protocols (gastrointestinal side effects, rare pancreatitis and gallbladder concerns).

Telehealth-heavy model. Many weight-loss clinics operate primarily by telehealth with optional in-person visits.

Compliance specifics: - DEA registration for Schedule III/IV prescribing - Ryan Haight Act compliance for telehealth controlled-substance prescribing - State-specific telehealth statutes - Compounding pharmacy partnership (verify USP-797 compliance, state distribution rules) - HIPAA-compliant patient communication infrastructure

Integration with aesthetic medspa:

Many NP-owned aesthetic medspas integrate a weight-loss service line. Patient overlap is significant — the same demographic seeks weight management, body contouring, and aesthetic injectables. Adding GLP-1 to an existing medspa typically requires: - DEA registration (if not already in place) - Additional protocols and consent forms - Lab partnership (Labcorp, Quest, or in-house CLIA-waived) - Compounding pharmacy account - Adjusted patient communication infrastructure for ongoing monitoring

My Practice Academy includes the GLP-1 / weight-loss launch module for members adding this service line to an existing aesthetic practice or launching as a primary service line.